Literature DB >> 17287080

Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.

Lei Wang1, Lan Yu, Guang He, Jing Zhang, Ai-Ping Zhang, Jing Du, Rui-Qi Tang, Xin-Zhi Zhao, Jie Ma, Jie-Kun Xuan, Yue Xiao, Niu-Fan Gu, Guo-Ying Feng, Ming-Qing Xu, Qing-He Xing, Lin He.   

Abstract

Serotonin transporter (5-HTT) is a key component of the serotonergic neurotransmitter system. Few studies have focused on polymorphisms of the serotonin transporter and antipsychotic response and, in particular, there have so far been no published studies on the association between the serotonin transporter and response to risperidone. This study examined the relationship between two polymorphisms of the serotonin transporter and the efficacy of risperidone treatment in 129 patients with schizophrenia. Our results revealed that patients with l allele of HTTRLP showed a greater improvement than those without l allele on the overall brief psychiatric rating scale (BPRS) (P=0.025). But no such relationship was found for the HTTVNTR. In haplotype analysis, the frequency of L-12 haplotype showed a significant difference between the responder group and the non-responder group (P=0.005). Our study has, for the first time, produced evidence that the potential for therapy in patients with schizophrenia is related to the HTTRLP polymorphism in the HTT gene and haplotype L-12 may help to predict risperidone treatment efficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287080     DOI: 10.1016/j.neulet.2006.09.014

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 2.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 4.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

5.  The pharmacogenetics of symptom response to antipsychotic drugs.

Authors:  Gavin P Reynolds
Journal:  Psychiatry Investig       Date:  2012-01-09       Impact factor: 2.505

Review 6.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

7.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

8.  Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.

Authors:  Mingqing Xu; Sheng Li; Qinghe Xing; Rui Gao; Guoyin Feng; Zhiguang Lin; David St Clair; Lin He
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

9.  Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.

Authors:  Ran Huo; Kefu Tang; Zhiyun Wei; Lu Shen; Yuyu Xiong; Xi Wu; Jiamin Niu; Xia Han; Zhengan Tian; Lun Yang; Guoyin Feng; Lin He; Shengying Qin
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

10.  Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone.

Authors:  Atsushi Tsutsumi; Tetsufumi Kanazawa; Hiroki Kikuyama; Gaku Okugawa; Hiroyuki Uenishi; Toshio Miyamoto; Naoki Matsumoto; Jun Koh; Kazuhiro Shinosaki; Toshifumi Kishimoto; Hiroshi Yoneda; Toshihiko Kinoshita
Journal:  Psychiatry Investig       Date:  2009-08-03       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.